The Global Health Body Raises Concern Over Critical Scarcity of Weight-Loss Medications
Less than 10% of people who could benefit from weight-loss injections like Wegovy can access them, states the WHO as it releases its inaugural recommendations on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication.
Based on forecasts, more than two billion are projected to be obese by 2030 without intervention.
"Our latest guidelines recognises that excess weight is a chronic disease that can be addressed with thorough and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant obstacles to widespread availability to the injections that can aid individuals in losing substantial weight, explains the agency.
Weight-Loss Drug Supply Crisis
Despite the present best projected case, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.
The recommendation encourages nations and manufacturers to increase availability, through measures such as voluntary licensing.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs replicate a natural hormone to reduce digestion speed, suppress the appetite and increase satiety so people consume fewer calories.
Patients commonly start to lose weight within a few weeks of beginning the weekly injections.
Evidence indicates people may put most of the weight back on a year later of stopping the drug, as their typical appetite come back.
To be overweight or obese raises your likelihood for experiencing health problems, including diabetes, heart disease, brain attack, and some cancers.
Excess weight concerns individuals in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
